These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23238625)

  • 1. Oral diabetes medications: an update for home health clinicians.
    Jacobs JA; Fetzer SJ
    Home Healthc Nurse; 2013 Jan; 31(1):E1-13. PubMed ID: 23238625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent safety updates on type 2 diabetes medications: a case report and the evidence for choosing among several available drugs for this patient.
    Sisson EM; Mills J; Chin L
    Am J Nurs; 2012 Dec; 112(12):49-53. PubMed ID: 23190674
    [No Abstract]   [Full Text] [Related]  

  • 3. Can genetics improve precision of therapy in diabetes?
    Groop L; Storm P; Rosengren A
    Trends Endocrinol Metab; 2014 Sep; 25(9):440-3. PubMed ID: 25028244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which oral agent to use when metformin is no longer effective?
    Bannon M
    QJM; 2011 Mar; 104(3):183-4. PubMed ID: 21330402
    [No Abstract]   [Full Text] [Related]  

  • 5. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of noninsulin antidiabetic medications in hospitalized patients.
    Kopecky C
    Crit Care Nurs Clin North Am; 2013 Mar; 25(1):39-53. PubMed ID: 23410645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The backbone of oral glucose-lowering therapy: time for a paradigm shift?
    Seufert J
    Fundam Clin Pharmacol; 2009 Dec; 23(6):651-67. PubMed ID: 19469803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Pro].
    Nauck MA
    Dtsch Med Wochenschr; 2011 Mar; 136(11):546. PubMed ID: 21351041
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral combination therapy in primary care.
    Kalra S; Gupta Y
    J Pak Med Assoc; 2015 May; 65(5):574-5. PubMed ID: 26028398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What to add in with metformin in type 2 diabetes?
    Petrie JR; Adler A; Vella S
    QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which oral drug is right for your type 2 diabetes? New thinking on oral drug combinations that can provide better glycemic control.
    Health News; 2005 Feb; 11(2):10-1. PubMed ID: 15732153
    [No Abstract]   [Full Text] [Related]  

  • 12. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
    Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
    [No Abstract]   [Full Text] [Related]  

  • 13. Pioglitazone/glimepiride (Duetact) for diabetes.
    Med Lett Drugs Ther; 2007 Jan; 49(1253):9-11. PubMed ID: 17261966
    [No Abstract]   [Full Text] [Related]  

  • 14. Diabetes under control: Understanding oral antidiabetic agents.
    Longo R
    Am J Nurs; 2010 Feb; 110(2):49-52. PubMed ID: 20107402
    [No Abstract]   [Full Text] [Related]  

  • 15. Pioglitazone + glimepiride: a combination product to avoid.
    Prescrire Int; 2007 Aug; 16(90):145. PubMed ID: 17724836
    [No Abstract]   [Full Text] [Related]  

  • 16. Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.
    Fang V; Wazny LD; Raymond CB
    CANNT J; 2012; 22(1):30-6; quiz 37-8. PubMed ID: 22558681
    [No Abstract]   [Full Text] [Related]  

  • 17. Rosiglitazone + glimepiride: new drug. Another combination product to avoid.
    Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17726795
    [No Abstract]   [Full Text] [Related]  

  • 18. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
    Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmacologic treatment of diabetes].
    De Montigny P; Clerc C; Descarpentries C
    Perspect Infirm; 2006; 4(2):30-4. PubMed ID: 17184094
    [No Abstract]   [Full Text] [Related]  

  • 20. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
    Bailey T
    Am J Med; 2013 Sep; 126(9 Suppl 1):S10-20. PubMed ID: 23953074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.